10-Q: Longevity Health Holdings Reports Q2 2026 Results, Faces Financial Challenges

Longevity Health Holdings, Inc. filed its Q2 2026 10-Q, revealing a significant net loss, declining sales, and substantial doubt about its ability to continue as a going concern.

Summary

• Longevity Health Holdings, Inc. reported its unaudited condensed consolidated financial statements for the quarter and six months ended June 30, 2026.
• The company experienced a net loss of $1.88 million for the three months ended June 30, 2026, and $3.31 million for the six months ended June 30, 2026.
• Net sales decreased by 21% to $395,991 for the three months ended June 30, 2026, and by 22% to $787,755 for the six months ended June 30, 2026, attributed to lower demand and increased competition.
• Operating expenses were significantly reduced, with general and administrative expenses down 56% for the three-month period and 33% for the six-month period.
• The company has substantial doubt about its ability to continue as a going concern due to its current cash position ($35,471 as of June 30, 2026), negative working capital, and ongoing losses.
• A significant event was the settlement of a legal dispute with Puritan Partners LLC, resulting in new convertible notes totaling $2.35 million.
• Management plans to alleviate going concern doubts include raising additional capital and acquiring cash flow-generating assets.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to significant net losses, a substantial decrease in net sales, and a precarious going concern status, despite some cost-saving measures.

Positives

• Significant reduction in operating expenses, particularly general and administrative costs (down 56% for Q2 2026 vs. Q2 2025) and selling and marketing expenses (down 45% for Q2 2026 vs. Q2 2025).
• Research and development expenses were also reduced by 68% for Q2 2026 compared to Q2 2025.
• The company successfully settled a significant legal dispute with Puritan Partners LLC, replacing existing convertible notes and warrants with new ones.
• A private placement on March 16, 2026, raised approximately $200,000 in gross proceeds.
• A new revolving credit facility with Shopify/WebBank provided $50,000 in June 2026.

Negatives

• Substantial net loss of $1.88 million for Q2 2026 and $3.31 million for the first six months of 2026.
• Net sales declined significantly: down 21% to $395,991 in Q2 2026 and down 22% to $787,755 in the first six months of 2026.
• The company faces substantial doubt about its ability to continue as a going concern, with only $35,471 in cash and negative working capital of $8,881,397 as of June 30, 2026.
• Increased competition in the bio-aesthetics market is cited as a reason for lower demand.
• The company recorded an inventory write-down of $38,917 for Q2 2026 and $235,601 for the first six months of 2026 due to expired raw materials and excess inventory.
• The settlement with Puritan Partners LLC resulted in new convertible notes totaling $2.35 million, increasing future financial obligations.
• The company's former Chairman and CEO, Rajiv Shukla, departed, with a separation agreement including potential severance payments.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to insufficient cash and ongoing losses.
• The company may need to raise additional capital through equity or debt issuances, with no assurance of availability on commercially acceptable terms.
• Increased competition in the bio-aesthetics market is impacting product demand.
• The company has one key supplier that accounts for a significant portion of inventory costs, posing a risk of production disruption if lost.
• The settlement with Puritan Partners LLC involves new senior secured convertible notes that are guaranteed by subsidiaries and secured by a first-priority lien on assets.
• The company's product pipeline includes regenerative bone and tissue healing products on which further research and development has been paused.

Future Outlook

The company's future outlook is uncertain due to its going concern status. Management plans to raise additional capital and potentially acquire cash flow-generating assets. The company's ability to commercialize products, manage growth, and secure financing are key factors for future performance.

Management Comments

• Management notes that the company is a bio-aesthetics company focused on longevity and healthy aging, with cosmetic skincare and haircare products.
• Management attributes the decrease in sales to lower demand and increased competition.
• Management is implementing cost efficiencies, including headcount reductions in the Elevai business line.
• Management acknowledges substantial doubt about the company's ability to continue as a going concern and outlines plans to raise additional capital and acquire cash flow-generating assets.

Industry Context

StockSavvy.ai notes that the bio-aesthetics market is competitive, as indicated by the company's declining sales and increased discounts. The company's focus on longevity and healthy aging aligns with growing consumer trends, but execution and financial stability remain critical challenges.

Comparison to Industry Standards

• The company's net sales have declined by 21% and 22% for the three and six-month periods ending June 30, 2026, respectively, which is a negative trend compared to growth-oriented companies in the beauty and wellness sector.
• The significant net losses and negative cash flow from operations are concerning and contrast with companies that have achieved profitability and positive cash flow.
• The company's reliance on external financing to fund operations is a common characteristic of early-stage or struggling companies, but the stated substantial doubt about going concern highlights a more severe liquidity risk than typical industry players.
• The settlement of a significant legal dispute with Puritan Partners LLC, while resolving a past issue, introduces new debt obligations that will impact future financial flexibility, a factor that needs careful management compared to companies with cleaner balance sheets.

Management Changes

Legal Proceedings

• Puritan Partners LLC v. Carmell Regen Med Corporation et al.: A settlement agreement was reached on August 13, 2026, resolving claims related to convertible notes and warrants. The company issued new convertible notes totaling $2.35 million.
• The company has disclosed material weaknesses in internal controls over financial reporting, including issues with expense classification, accounting treatment for complex transactions, and stock-based compensation calculations.

Related Party Transactions

• On March 16, 2026, the company closed a private placement with International Capital Partners LLC (ICP), raising $200,000. Janakiram Ajjarapu, the new Chairman and CEO, is the managing member of ICP.

Stakeholder Impact

• Shareholders: The company's financial distress and ongoing losses, coupled with a declining stock price (implied by low share price and going concern issues), negatively impact shareholder value. The issuance of new convertible notes could lead to further dilution upon conversion.
• Creditors: The company's substantial liabilities and going concern issues increase the risk for creditors. The new senior secured convertible notes issued to Puritan Partners LLC have priority claims.
• Employees: Cost-saving measures, including headcount reductions, may impact employee morale and job security. The departure of the former CEO also creates leadership uncertainty.
• Suppliers: The company's financial instability could lead to delayed payments or potential disruptions in the supply chain, especially given the reliance on a single key supplier.

Next Steps

• The company will continue to evaluate its financial condition and explore options for raising additional capital.
• Management will focus on cost efficiencies and potentially acquiring cash flow-generating assets.
• The company is required to file a registration statement covering resale of shares issuable upon conversion of the new Puritan notes within 30 days of August 13, 2026.
• The company will file a stipulation dismissing the Puritan action without prejudice within 3 business days of August 13, 2026.

Key Dates

Recommendation

The company exhibits severe financial distress, characterized by significant net losses, declining revenues, a critical going concern status with minimal cash reserves, and substantial new debt obligations. Despite cost-cutting measures, the path to profitability and sustainable operations is highly uncertain, making it a high-risk investment.

Keywords

bio-aesthetics, skincare, haircare, longevity, healthy aging, asset acquisition, convertible notes, legal settlement